With the recent price changes around Mounjaro, many people are now looking at Wegovy as an alternative. If you’re weighing up the switch, it helps to understand how the two treatments compare. While there are some differences in average weight loss outcomes, both are proven to be very effective options for long-term weight management.
How Do They Compare?
Mounjaro (Tirzepatide)
- Average weight loss: Around 20–22% of starting weight after 72 weeks (depending on dose).
- How it works: Mounjaro is unique in that it activates both GIP and GLP-1 receptors—hormones that naturally regulate hunger and blood glucose. This dual action helps you feel full sooner, stay satisfied longer, and eat less overall.
- How it’s taken: Once-weekly injection.
Wegovy (Semaglutide)
- Weight loss: Around 20.7% of starting body weight at 72 weeks, in the latest STEP UP Trial.
- How it works: Wegovy targets GLP-1 receptors. By mimicking the GLP-1 hormone, it signals fullness to your brain, reducing appetite and cravings.
- How it’s taken: Once-weekly injection.
Even a 5–10% reduction in body weight can deliver big health benefits such as lowering blood pressure, improving blood glucose control, and reducing risk for weight-related conditions.
The Real Foundation of Success
Whether you’re prescribed Mounjaro or Wegovy, it’s important to remember that the medication is just one part of the picture. These treatments make it easier to manage appetite, but they work best when combined with sustainable lifestyle habits.
Think of them like a supportive handrail - they can steady you on your journey, but you still need to take the steps. Those steps rest on four main pillars:
- Nutrition – Building a way of eating that is balanced, enjoyable, and realistic for the long term.
- Activity – Moving regularly in ways that fit your life. It doesn’t need to be intense, consistency matters most.
- Stress management – Finding positive strategies to manage stress, since high stress can trigger cravings and poor sleep.
- Sleep – Good-quality rest helps regulate hunger, energy, and mood.
When these are in place, medication has the biggest impact; without them, even the strongest treatment may not deliver lasting change.
Support Along the Way
No matter which option you choose—Mounjaro or Wegovy—you’ll have access to:
- The GLP-1 Nutrition Guide (designed for those on GLP-1 medications)
- Complimentary weight loss kit (sharps bin + spare needles)
- Monthly check-ins with our clinical team
- Dedicated Patient Care Team, 7 days a week
- Advice emails and tailored weight loss maintenance support
You don’t need to go through this process on your own - we’ll be here every step of the way.
Switching from Mounjaro to Wegovy isn’t about losing effectiveness, it’s about choosing the treatment that aligns best with your needs and goals. Both medications can help deliver meaningful improvements when paired with supportive lifestyle changes.
If you’re considering making the change, our team is here to provide the guidance and support you need to move forward with confidence.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216. Link
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002. Link
- Garvey W, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083–2091. Link
- Sjöström L, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167–172. Link
- Davidson MH, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235–242. Link
- Lingvay, I., Bergenheim, S. J., Buse, J. B., Freitas, P., Garvey, W. T., Harder-Lauridsen, N. M., Rosenstock, J., Sahu, K., Wharton, S., & STEP UP T2D trial group (2025). Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology, S2213-8587(25)00225-6. Advance online publication.
